<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04367103</url>
  </required_header>
  <id_info>
    <org_study_id>ShA</org_study_id>
    <nct_id>NCT04367103</nct_id>
  </id_info>
  <brief_title>Norepinephrine for Hypotension in Cesarean Section</brief_title>
  <official_title>Norepinephrine or Phenylephrine for Hypotension in Non-elective Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypotension is a very common consequence of the sympathetic vasomotor block caused by spinal
      anesthesia for cesarean section. Maternal symptoms such as nausea, vomiting and dyspnea
      frequently accompany severe hypotension, and adverse effects on the fetus, including
      depressed APGAR scores and umbilical acidosis, have been correlated with severity and
      duration of hypotension. Because hypotension is frequent, vasopressors should be used
      routinely and preferably prophylactically.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phenylephrine has a potent direct α effect, with virtually no β effects at clinical doses,
      however when given at higher than required doses, it may induce baroreceptor-mediated
      bradycardia with a consequent reduction in maternal cardiac output. Although α agonist drugs
      are the most appropriate agents to treat or prevent hypotension following spinal anaesthesia,
      those with a small amount of β agonist activity may have the best profile (noradrenaline
      (norepinephrine) and metaraminol. Phenylephrine is currently recommended due to the amount of
      supporting data.Noradrenaline is the primary catecholamine released by postganglionic
      adrenergic nerves. It is a potent α adrenergic agonist, with comparatively modest β agonist
      activity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of hypotensive episodes.</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>Hypotension is defined as &lt;80% of baseline or systolic blood pressure (SBP) &lt;100 mmHg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of maternal bradycardia.</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>Bradycardia is defined as heart rate (HR) &lt; 50 beats/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of reactive hypertension</measure>
    <time_frame>20 minutes</time_frame>
    <description>defined as &gt;120% of baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nausea and vomiting</measure>
    <time_frame>20 minutes</time_frame>
    <description>Incidence of nausea and vomiting attacks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of vasopressor</measure>
    <time_frame>20 minutes</time_frame>
    <description>Total dose of vasopressor used.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fetal outcome</measure>
    <time_frame>at 1, 5 and 8 minutes</time_frame>
    <description>APGAR score</description>
  </other_outcome>
  <other_outcome>
    <measure>mixed blood gas</measure>
    <time_frame>1 minute after delivery</time_frame>
    <description>Umbilical artery and vein blood gas</description>
  </other_outcome>
  <other_outcome>
    <measure>Admission to neonatal ICU (NICU)</measure>
    <time_frame>first 24 hours after delivery</time_frame>
    <description>the need for NICU admission</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypotension</condition>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>NEP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norepinephrine infusion of 0.025 µg/kg/min and 6 µg bolus will be used if BP is reduced 20 % below baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHE group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phenylephrine will be started at 25µg/min immediately after the intrathecal local anaesthetic injection and titrated according to blood pressure and pulse rate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>prophylaxis for hypotension</description>
    <arm_group_label>NEP group</arm_group_label>
    <other_name>noradrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>standerd prophylaxis for hypotension</description>
    <arm_group_label>PHE group</arm_group_label>
    <other_name>phenylephrine hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who fall in category 2 and 3 according to the classification of Caesarean
             section made by Royal College of Obstetrician and Gynaecologists.

        Exclusion Criteria:

          -  Patient refusal either to study enrollment or to spinal anesthesia.

               -  Any absolute contraindication to spinal anesthesia e.g. coagulopathy, skin
                  infection at site of injection.

               -  Allergy to any of study drugs.

               -  Patients with cardiac morbidities, hypertensive disorders or peripartum bleeding

               -  BMI &gt; 40 kg/m²

               -  Baseline systolic blood pressure &lt; 100 mmHg.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed M. Abdellatif, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shimaa A. Husien, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed S. Mostafa, M.B.B.Ch</last_name>
    <phone>+20882413201</phone>
    <email>drmohameds.mostafa93@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed A. Ebrahiem, M.D.</last_name>
    <phone>+20882413201</phone>
    <email>Ahmedfotoh88@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <email>shimaa.abbas@med.aun.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Shimaa Abbas Hassan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>post spinal anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

